Printer Friendly

JHL Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma.

JHL Biotech announced today that the Center for Drug Evaluation (CDE), State Drug Administration of China (SDA) has approved JHL's Phase I and Phase III Clinical Trial Application for a proposed rituximab biosimilar, JHL1101, to treat non-Hodgkin lymphoma. JHL will begin clinical trials of JHL1101 in the following months, Tuesday (7/6).

Racho Jordanov, JHL Biotech's Co-Chairman and CEO stated, 'This study adds to the data collected in the JHL1101 EU study and will differentiate JHL from many of its competitors. JHL Biotech is one of the few companies conducting clinical trials with biosimilars globally.'

About JHL Biotech

JHL Biotech Inc. is a biopharmaceutical company founded by a group of industry veterans with deep experience in biologics development and operations. With a mission to provide the world with affordable medicines of exceptional quality, the company is focused on research and development of new protein-based therapies and biosimilars.

JHL Biotech's experienced leadership team, ongoing global clinical trials for its pipeline of biosimilar candidates and two Asia-based world-class biologics manufacturing facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards uniquely position the company to be a leading global supplier of high quality biologics.

JHL Biotech is backed by premier financial firms, including Kleiner Perkins Caufield and Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity and the China Development Industrial Bank. For more information, please visit www.jhlbiotech.com.

COPYRIGHT 2018 Asianet-Pakistan
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The President Post (Jakarta, Indonesia)
Date:Jul 31, 2018
Words:276
Previous Article:HistoIndex Welcomes Its New CEO on Board.
Next Article:The Inaugural Fullerton Concours d'Elegance Concluded on a High Note, Bringing together Communities in Celebration of the Iconic Fullerton Building's...
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |